Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney | 31 | 2020 | 945 | 1.550 |
Why?
|
| Hypertension, Renovascular | 13 | 1996 | 47 | 1.000 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2019 | 15 | 0.850 |
Why?
|
| Publishing | 2 | 2014 | 89 | 0.710 |
Why?
|
| Yellow Fever | 1 | 2018 | 1 | 0.670 |
Why?
|
| Renal Dialysis | 7 | 2021 | 174 | 0.670 |
Why?
|
| Hyponatremia | 2 | 2010 | 20 | 0.610 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 202 | 0.580 |
Why?
|
| Proteinuria | 2 | 2018 | 136 | 0.570 |
Why?
|
| Angiotensin II | 15 | 1995 | 220 | 0.540 |
Why?
|
| Kidney Glomerulus | 15 | 2019 | 155 | 0.540 |
Why?
|
| Military Personnel | 1 | 2018 | 220 | 0.530 |
Why?
|
| Narration | 1 | 2015 | 29 | 0.530 |
Why?
|
| Attitude to Death | 1 | 2015 | 52 | 0.530 |
Why?
|
| Sodium | 11 | 2010 | 161 | 0.510 |
Why?
|
| Scientific Misconduct | 1 | 2014 | 12 | 0.510 |
Why?
|
| Physicians | 1 | 2018 | 324 | 0.500 |
Why?
|
| Kidney Failure, Chronic | 5 | 2020 | 365 | 0.480 |
Why?
|
| Hypertension | 9 | 2021 | 1531 | 0.440 |
Why?
|
| Ganglionic Stimulants | 1 | 2012 | 15 | 0.430 |
Why?
|
| Kidney Tubules | 14 | 1991 | 80 | 0.400 |
Why?
|
| Homeostasis | 7 | 2010 | 291 | 0.400 |
Why?
|
| Blood Pressure | 21 | 2021 | 1447 | 0.390 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 121 | 0.390 |
Why?
|
| Renal Circulation | 10 | 2008 | 49 | 0.360 |
Why?
|
| Cardiology | 1 | 2010 | 140 | 0.350 |
Why?
|
| Nicotine | 1 | 2012 | 350 | 0.330 |
Why?
|
| Bradykinin | 5 | 2008 | 157 | 0.330 |
Why?
|
| Rats | 38 | 2008 | 5300 | 0.280 |
Why?
|
| Glomerular Filtration Rate | 24 | 1987 | 274 | 0.280 |
Why?
|
| Administrative Personnel | 1 | 2006 | 22 | 0.280 |
Why?
|
| Clinical Medicine | 1 | 2006 | 20 | 0.270 |
Why?
|
| Membrane Transport Proteins | 1 | 2006 | 81 | 0.270 |
Why?
|
| Disaster Planning | 1 | 2006 | 105 | 0.270 |
Why?
|
| Hypertension, Renal | 9 | 1983 | 29 | 0.260 |
Why?
|
| History, 19th Century | 2 | 2018 | 95 | 0.260 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 1996 | 201 | 0.250 |
Why?
|
| Oligopeptides | 6 | 1987 | 152 | 0.250 |
Why?
|
| Disasters | 1 | 2006 | 204 | 0.250 |
Why?
|
| History, 20th Century | 2 | 2018 | 248 | 0.240 |
Why?
|
| Kinins | 3 | 2008 | 109 | 0.240 |
Why?
|
| Renin-Angiotensin System | 5 | 1990 | 78 | 0.240 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2021 | 140 | 0.230 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2003 | 19 | 0.230 |
Why?
|
| Animals | 47 | 2012 | 20877 | 0.230 |
Why?
|
| Teprotide | 8 | 1987 | 8 | 0.230 |
Why?
|
| Bradykinin Receptor Antagonists | 3 | 1998 | 20 | 0.220 |
Why?
|
| Nephritis, Hereditary | 1 | 2002 | 8 | 0.220 |
Why?
|
| Sodium Chloride | 9 | 2006 | 136 | 0.210 |
Why?
|
| Renin | 12 | 1983 | 96 | 0.210 |
Why?
|
| Humans | 26 | 2021 | 68525 | 0.200 |
Why?
|
| Heart Failure | 1 | 2010 | 1179 | 0.200 |
Why?
|
| Nephritis, Interstitial | 1 | 2020 | 14 | 0.180 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2019 | 3 | 0.180 |
Why?
|
| Eosinophilia | 1 | 2020 | 47 | 0.180 |
Why?
|
| Amyloidosis | 1 | 2019 | 48 | 0.170 |
Why?
|
| Graft Survival | 1 | 2002 | 465 | 0.170 |
Why?
|
| Kidney Transplantation | 2 | 2009 | 839 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 161 | 0.170 |
Why?
|
| Mosquito Vectors | 1 | 2018 | 3 | 0.170 |
Why?
|
| Cuba | 1 | 2018 | 8 | 0.170 |
Why?
|
| Postpartum Period | 1 | 2018 | 67 | 0.160 |
Why?
|
| Enalapril | 2 | 1996 | 86 | 0.160 |
Why?
|
| Male | 29 | 2020 | 37281 | 0.160 |
Why?
|
| Kidney Tubules, Proximal | 8 | 1996 | 81 | 0.160 |
Why?
|
| Potassium | 7 | 1986 | 168 | 0.160 |
Why?
|
| Chlorides | 4 | 1996 | 68 | 0.160 |
Why?
|
| Feedback | 14 | 1991 | 90 | 0.150 |
Why?
|
| Biphenyl Compounds | 2 | 1995 | 184 | 0.150 |
Why?
|
| Acute Disease | 1 | 2018 | 658 | 0.150 |
Why?
|
| Rats, Inbred Strains | 10 | 1996 | 532 | 0.150 |
Why?
|
| Calciphylaxis | 1 | 1996 | 7 | 0.140 |
Why?
|
| Enalaprilat | 1 | 1996 | 4 | 0.140 |
Why?
|
| Kidney Tubules, Collecting | 1 | 1996 | 46 | 0.140 |
Why?
|
| Hemodynamics | 7 | 1996 | 705 | 0.140 |
Why?
|
| Receptor, Bradykinin B2 | 4 | 2008 | 75 | 0.140 |
Why?
|
| Health Resources | 1 | 2016 | 76 | 0.130 |
Why?
|
| Kidney Medulla | 3 | 2008 | 17 | 0.130 |
Why?
|
| Water | 2 | 1996 | 228 | 0.130 |
Why?
|
| Plagiarism | 1 | 2014 | 2 | 0.130 |
Why?
|
| Epidemics | 1 | 2014 | 12 | 0.130 |
Why?
|
| Tetrazoles | 1 | 1995 | 160 | 0.120 |
Why?
|
| Imidazoles | 1 | 1995 | 175 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1995 | 155 | 0.120 |
Why?
|
| Ureteral Obstruction | 1 | 1994 | 25 | 0.120 |
Why?
|
| Female | 15 | 2020 | 38015 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2003 | 1241 | 0.120 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 938 | 0.120 |
Why?
|
| Natriuresis | 5 | 1986 | 13 | 0.120 |
Why?
|
| Receptors, Thromboxane | 1 | 1994 | 122 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 497 | 0.120 |
Why?
|
| Adult | 8 | 2020 | 21375 | 0.110 |
Why?
|
| Pregnancy | 1 | 2018 | 2331 | 0.110 |
Why?
|
| Rural Population | 1 | 2016 | 397 | 0.110 |
Why?
|
| Diuretics | 2 | 2010 | 96 | 0.100 |
Why?
|
| Enzyme Inhibitors | 3 | 2001 | 659 | 0.100 |
Why?
|
| Nephrons | 7 | 1984 | 17 | 0.100 |
Why?
|
| Kidney Diseases | 2 | 1994 | 307 | 0.100 |
Why?
|
| Ultrafiltration | 1 | 2010 | 35 | 0.090 |
Why?
|
| Vascular Resistance | 9 | 1996 | 179 | 0.090 |
Why?
|
| Saralasin | 4 | 1982 | 5 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2010 | 136 | 0.090 |
Why?
|
| Heart Conduction System | 1 | 2010 | 119 | 0.090 |
Why?
|
| Algorithms | 1 | 2016 | 1194 | 0.090 |
Why?
|
| Mass Screening | 1 | 2016 | 837 | 0.090 |
Why?
|
| Captopril | 2 | 1991 | 22 | 0.090 |
Why?
|
| Leadership | 1 | 2010 | 135 | 0.090 |
Why?
|
| Acetylglucosamine | 1 | 2009 | 46 | 0.090 |
Why?
|
| Education, Medical | 1 | 2010 | 147 | 0.080 |
Why?
|
| Urine | 2 | 2006 | 47 | 0.080 |
Why?
|
| Kidney Function Tests | 3 | 2006 | 114 | 0.080 |
Why?
|
| Biopsy | 2 | 2020 | 539 | 0.080 |
Why?
|
| Verapamil | 1 | 1987 | 30 | 0.080 |
Why?
|
| Body Weight | 4 | 2017 | 554 | 0.080 |
Why?
|
| Mississippi | 1 | 2006 | 11 | 0.070 |
Why?
|
| Dogs | 5 | 1981 | 490 | 0.070 |
Why?
|
| Louisiana | 1 | 2006 | 37 | 0.070 |
Why?
|
| Sympathetic Nervous System | 1 | 1986 | 81 | 0.070 |
Why?
|
| Regional Blood Flow | 5 | 1996 | 168 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1085 | 0.070 |
Why?
|
| Osmolar Concentration | 4 | 2006 | 134 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2009 | 458 | 0.070 |
Why?
|
| Acute Kidney Injury | 2 | 1979 | 232 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2006 | 149 | 0.070 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 357 | 0.070 |
Why?
|
| Kidney Tubules, Distal | 6 | 1982 | 15 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 1082 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2020 | 1039 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 1446 | 0.060 |
Why?
|
| Calcium | 2 | 2001 | 929 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 1996 | 371 | 0.060 |
Why?
|
| Proline | 1 | 1984 | 52 | 0.060 |
Why?
|
| Absorption | 3 | 1996 | 49 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2006 | 225 | 0.060 |
Why?
|
| Vasopressins | 1 | 2003 | 33 | 0.060 |
Why?
|
| Middle Aged | 7 | 2020 | 21119 | 0.060 |
Why?
|
| Angiotensins | 1 | 1982 | 16 | 0.060 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2002 | 15 | 0.050 |
Why?
|
| Kidney Cortex | 1 | 1981 | 19 | 0.050 |
Why?
|
| Receptors, Bradykinin | 1 | 2001 | 50 | 0.050 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2001 | 43 | 0.050 |
Why?
|
| Calmodulin | 1 | 2001 | 53 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2021 | 87 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2003 | 346 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 195 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1293 | 0.050 |
Why?
|
| Nephrosis, Lipoid | 1 | 2019 | 9 | 0.050 |
Why?
|
| Sclerosis | 1 | 2019 | 32 | 0.050 |
Why?
|
| Eosinophils | 1 | 2020 | 60 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2020 | 42 | 0.040 |
Why?
|
| Myoglobinuria | 1 | 1979 | 1 | 0.040 |
Why?
|
| Hypokalemia | 1 | 1979 | 12 | 0.040 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1979 | 22 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 243 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2020 | 272 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 1979 | 39 | 0.040 |
Why?
|
| Plasma Volume | 1 | 1978 | 5 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2008 | 2083 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 411 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5719 | 0.040 |
Why?
|
| Albuminuria | 2 | 1996 | 171 | 0.040 |
Why?
|
| Diuresis | 2 | 1996 | 20 | 0.040 |
Why?
|
| Veins | 1 | 2017 | 68 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 104 | 0.040 |
Why?
|
| Systole | 1 | 2017 | 149 | 0.040 |
Why?
|
| Ischemia | 1 | 1978 | 229 | 0.040 |
Why?
|
| Hypotension | 1 | 2017 | 74 | 0.040 |
Why?
|
| Arteries | 1 | 2017 | 108 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 3702 | 0.040 |
Why?
|
| Phosphorus | 1 | 1996 | 64 | 0.040 |
Why?
|
| Skin Ulcer | 1 | 1996 | 19 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 1996 | 51 | 0.040 |
Why?
|
| Thrombosis | 1 | 2017 | 218 | 0.040 |
Why?
|
| Hospitalization | 2 | 2017 | 977 | 0.040 |
Why?
|
| Parathyroidectomy | 1 | 1996 | 45 | 0.040 |
Why?
|
| Albumins | 1 | 1996 | 72 | 0.040 |
Why?
|
| Diet, Sodium-Restricted | 2 | 2008 | 45 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1139 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1037 | 0.030 |
Why?
|
| Tanzania | 1 | 2016 | 35 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 164 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1996 | 43 | 0.030 |
Why?
|
| Glomerulonephritis | 1 | 1996 | 77 | 0.030 |
Why?
|
| Blood Vessels | 1 | 1996 | 102 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1548 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1996 | 223 | 0.030 |
Why?
|
| Losartan | 1 | 1995 | 45 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2356 | 0.030 |
Why?
|
| Reference Values | 1 | 1996 | 579 | 0.030 |
Why?
|
| Organ Size | 1 | 1995 | 242 | 0.030 |
Why?
|
| Aged | 3 | 2018 | 14842 | 0.030 |
Why?
|
| Osmotic Pressure | 2 | 1985 | 8 | 0.030 |
Why?
|
| Random Allocation | 1 | 1995 | 442 | 0.030 |
Why?
|
| Heptanoic Acids | 1 | 1994 | 28 | 0.030 |
Why?
|
| Autoantibodies | 1 | 1996 | 434 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1341 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1993 | 40 | 0.030 |
Why?
|
| Urodynamics | 3 | 1981 | 43 | 0.030 |
Why?
|
| Hydrostatic Pressure | 3 | 1981 | 11 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2264 | 0.030 |
Why?
|
| Prognosis | 1 | 1996 | 2093 | 0.020 |
Why?
|
| Adolescent | 1 | 2003 | 8903 | 0.020 |
Why?
|
| Peptides | 1 | 1993 | 455 | 0.020 |
Why?
|
| Angiotensin I | 2 | 1979 | 24 | 0.020 |
Why?
|
| Hemostasis | 1 | 2009 | 32 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1515 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3256 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2222 | 0.020 |
Why?
|
| Bradykinin B2 Receptor Antagonists | 1 | 2008 | 13 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2008 | 23 | 0.020 |
Why?
|
| Research | 1 | 1990 | 214 | 0.020 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2008 | 50 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 4655 | 0.020 |
Why?
|
| Denervation | 1 | 1986 | 23 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1987 | 276 | 0.020 |
Why?
|
| Atlantic Ocean | 1 | 2006 | 22 | 0.020 |
Why?
|
| Acclimatization | 1 | 2006 | 14 | 0.020 |
Why?
|
| Seawater | 1 | 2006 | 29 | 0.020 |
Why?
|
| Fresh Water | 1 | 2006 | 43 | 0.020 |
Why?
|
| Hematocrit | 1 | 1985 | 70 | 0.020 |
Why?
|
| Blood Volume | 1 | 1985 | 47 | 0.020 |
Why?
|
| Mannitol | 3 | 1980 | 25 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1983 | 317 | 0.020 |
Why?
|
| Body Fluids | 1 | 1984 | 41 | 0.020 |
Why?
|
| Perfusion | 3 | 1980 | 131 | 0.020 |
Why?
|
| Appetite | 1 | 1983 | 16 | 0.010 |
Why?
|
| Cost Allocation | 1 | 2003 | 4 | 0.010 |
Why?
|
| Fees and Charges | 1 | 2003 | 11 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 2003 | 28 | 0.010 |
Why?
|
| Extracellular Space | 1 | 1983 | 121 | 0.010 |
Why?
|
| Aldosterone | 1 | 1983 | 51 | 0.010 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2003 | 69 | 0.010 |
Why?
|
| Drug Costs | 1 | 2003 | 87 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1983 | 138 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2003 | 117 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 1982 | 59 | 0.010 |
Why?
|
| Urea | 2 | 1980 | 51 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 254 | 0.010 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1981 | 31 | 0.010 |
Why?
|
| Furosemide | 2 | 1978 | 45 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 2001 | 24 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 281 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2001 | 60 | 0.010 |
Why?
|
| Juxtaglomerular Apparatus | 1 | 1981 | 7 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2001 | 72 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2001 | 40 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 1981 | 29 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1981 | 43 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 2001 | 67 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1982 | 765 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1981 | 206 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1979 | 48 | 0.010 |
Why?
|
| Diet | 1 | 1983 | 513 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 618 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1047 | 0.010 |
Why?
|
| Desoxycorticosterone | 1 | 1978 | 41 | 0.010 |
Why?
|
| Hypotonic Solutions | 1 | 1978 | 4 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1978 | 25 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 1425 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 562 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1983 | 2550 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1978 | 21 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1981 | 475 | 0.010 |
Why?
|
| Kidney Concentrating Ability | 1 | 1978 | 3 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1032 | 0.010 |
Why?
|
| Pressure | 1 | 1978 | 252 | 0.010 |
Why?
|
| Magnesium | 1 | 1978 | 110 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 711 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1978 | 205 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 1752 | 0.010 |
Why?
|
| Glucose | 1 | 1978 | 307 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 981 | 0.010 |
Why?
|
| South Carolina | 1 | 2003 | 2750 | 0.010 |
Why?
|
| Microinjections | 1 | 1996 | 130 | 0.010 |
Why?
|
| Heart Rate | 1 | 1998 | 568 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 4843 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2001 | 2688 | 0.010 |
Why?
|
| Mice | 1 | 2001 | 8472 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 1986 | 95 | 0.000 |
Why?
|
| Tetraphenylborate | 1 | 1986 | 1 | 0.000 |
Why?
|
| Valinomycin | 1 | 1986 | 3 | 0.000 |
Why?
|
| Photometry | 1 | 1986 | 6 | 0.000 |
Why?
|
| Online Systems | 1 | 1986 | 20 | 0.000 |
Why?
|
| Electrodes | 1 | 1986 | 147 | 0.000 |
Why?
|
| Capillaries | 1 | 1984 | 105 | 0.000 |
Why?
|
| Prostaglandins | 1 | 1982 | 65 | 0.000 |
Why?
|
| Administration, Topical | 1 | 1982 | 111 | 0.000 |
Why?
|
| p-Aminohippuric Acid | 1 | 1982 | 3 | 0.000 |
Why?
|
| Renal Artery | 1 | 1981 | 29 | 0.000 |
Why?
|
| Glucocorticoids | 1 | 1982 | 222 | 0.000 |
Why?
|
| Electrolytes | 1 | 1980 | 47 | 0.000 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1982 | 234 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1980 | 172 | 0.000 |
Why?
|
| Radiography | 1 | 1981 | 572 | 0.000 |
Why?
|
| Osmotic Fragility | 1 | 1978 | 2 | 0.000 |
Why?
|
| Hypertonic Solutions | 1 | 1978 | 17 | 0.000 |
Why?
|
| Cell Membrane Permeability | 1 | 1978 | 59 | 0.000 |
Why?
|
| Loop of Henle | 1 | 1976 | 6 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1976 | 49 | 0.000 |
Why?
|
| Bromides | 1 | 1976 | 17 | 0.000 |
Why?
|
| Sulfates | 1 | 1976 | 28 | 0.000 |
Why?
|
| Magnesium Sulfate | 1 | 1976 | 6 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1976 | 160 | 0.000 |
Why?
|